Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foghorn Therapeutics Inc.
Report date August 31, 2022 · Filed September 02, 2022
Section 16 reporting ended · disclosed 2022-09-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 295,000 |
Reported balance
Holding disclosure · report date 2022-08-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 295,000 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,329,379 |
Reported balance
Holding disclosure · report date 2022-08-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,329,379 F1: Shares held by the Cigall Kadoch Revocable Trust of 2021, of which the Reporting Person is the sole trustee and sole current beneficiary. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.81 · Expires 2032-06-20 | Direct | 16,000 |
Reported balance
Holding disclosure · report date 2022-08-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 16,000 |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.40 · Expires 2031-07-12 | Direct | 12,530 |
Reported balance
Holding disclosure · report date 2022-08-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,530 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by the Cigall Kadoch Revocable Trust of 2021, of which the Reporting Person is the sole trustee and sole current beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2022 Filed Jun 23, 2022 00:59 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001562180-22-005316 · primarydocument.xml · derivative · entry 1 KADOCH CIGALL · CIK 0001828726 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-20 Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 00:20 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GiftCommon Stock | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007735 · primarydocument.xml · nonDerivative · entry 1 KADOCH CIGALL · CIK 0001828726 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 F1 · price: On December 14, 2021, the Reporting Person transferred 333,333 shares of Common Stock to the Cigall Kadoch Irrevocable Trust of 2021 (the "Irrevocable Trust"). The Reporting Person is not a trustee of the Irrevocable Trust and she exercises no investment discretion with respect to trust property therein. The Reporting Person and members of her immediate family are beneficiaries of the Irrevocable Trust. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:53 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 12,530 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-21-004934 · primarydocument.xml · derivative · entry 1 KADOCH CIGALL · CIK 0001828726 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,530 Underlying: Common Stock · 12,530 shares Expires 2031-07-12 F1 · derivative.exercise_date: The options will vest in full on the first anniversary of the date of grant, subject to the director's continued service on our Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.